Clinical Trials Sponsored by IQVIA RDS

Total 385 results

AstraZeneca
IQVIA RDS Inc.

Recruiting

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (CHIMES)

Lower Respiratory Tract Infection

China
Aboca Spa Societa' Agricola
IQVIA RDS; IQVIA Solutions

Recruiting

Oral Administration of Actitan-F in Paediatric Diarrhoea

Chronic Diarrhoea of Infants and/or Young Children

Italy
Aboca Spa Societa' Agricola
IQVIA RDS; IQVIA Solutions

Completed

Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Irritable Bowel Syndrome

Italy, Germany
AstraZeneca
IQVIA RDS (Shanghai) Co., Ltd.

Completed

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults (PK/ADA)

Evaluate PK Profile

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
IQVIA RDS

Recruiting

A Study Of IMM47 In Subjects With Advanced Solid Tumors

Oncology

Australia
Jovie USA, LLC
IQVIA RDS Inc.; ObvioHealth

Completed

Growth and Safety Clinical Trial on a New Infant Formula

Weight Gain

United States
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
R-Pharm International, LLC
IQVIA RDS Ireland Ltd; Thermo Fisher Scientific FS

Completed

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Rheumatoid Arthritis

Bulgaria, Moldova, Republic of
Gilead Sciences
Parexel; IQVIA RDS (Shanghai) Co., Ltd.; Medidata Solutions; Q Squared Solutions...

Active, not recruiting

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Metastatic Triple-negative Breast Cancer

China
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
Iqvia Pty Ltd

Completed

COVID-19 Active Research Experience (CARE)

COVID-19

United States, United Kingdom
Iqvia Pty Ltd

Terminated

Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours

Cancer - Solid Tumours

Australia
Synlogic
IQVIA Biotech

Recruiting

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects

Lymphoma | Metastatic Solid Neoplasm

United States
argenx
Iqvia Pty Ltd

Recruiting

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome (Rho plus)

Primary Sjögren's Syndrome

Belgium, Hungary, Poland
AstraZeneca
Iqvia Pty Ltd

Recruiting

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip SC)

Systemic Lupus Erythematosus

Germany, Hungary, Japan, Mexico, United States, Argentina, Bulgaria, Chile, Colombia, Peru, Poland, Spain, Ukraine, United Kingdom, Russian Federation
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)

SCLC | Breast | Ovarian | Gastric Cancers

United Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
Blueberry Therapeutics
IQVIA Biotech

Completed

A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

Fungal Infection | Distal Subungual Onychomycosis | Fungus, Nail

Poland, Germany, Czechia
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
GlaxoSmithKline
Iqvia Pty Ltd

Active, not recruiting

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)

Multiple Myeloma

United States, Australia, Spain, United Kingdom, Canada
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AbbVie
IQVIA, formerly Quintiles

Completed

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United Kingdom, Czechia, United States, Australia, Canada, Israel, New Zealand, Poland, Portugal, Russian Federation, Thailand
AstraZeneca
Iqvia Pty Ltd

Terminated

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease (HESTIA3)

Sickle Cell Disease

Italy, Spain, United Kingdom, Belgium, United States, India, South Africa, Brazil, Turkey, Egypt, Ghana, Greece, Kenya, Lebanon, Tanzania, Uganda
Prokidney
Iqvia Pty Ltd

Not yet recruiting

A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease

Chronic Kidney Diseases | Type 2 Diabetes Mellitus
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)

Asthma

United States, Australia, Austria, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, Norway, Poland, Puerto Rico, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, Israel, Portugal
AstraZeneca
Iqvia Pty Ltd

Terminated

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (ARROYO)

Chronic Spontaneous Urticaria

United States, Germany, Korea, Republic of, Spain, Bulgaria, Poland, Japan
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (contRAst X)

Arthritis, Rheumatoid

United States, Germany, Japan, Korea, Republic of, Poland, Ukraine, Bulgaria, Canada, Czechia, Estonia, Hungary, Mexico, Russian Federation, South Africa, Spain, Malaysia, Thailand, China, Argentina, Belgium, India, United Kingdom, ... and more
argenx
Iqvia Pty Ltd

Active, not recruiting

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Postural Orthostatic Tachycardia Syndrome

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)

Respiratory Syncytial Virus Infections

Japan
Inozyme Pharma
IQVIA Biotech

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Pseudoxanthoma Elasticum | Generalized Arterial Calcification of Infancy | ATP-Binding Cassette Subfamily C Member 6 Deficiency

United States, United Kingdom
argenx
Iqvia Pty Ltd

Recruiting

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)

Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

United States
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)

Asthma

United States, Australia, Canada, France, Germany, Italy, Japan, Poland, Spain, China, Czechia, Hungary, Taiwan, United Kingdom
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India

Respiratory Tract Infections | Otitis Media | Infections, Respiratory Tract

India
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)

Arthritis, Rheumatoid

Hungary, Poland, Malaysia, Spain, China, Russian Federation, India, United Kingdom, Italy, Serbia
Mersana Therapeutics
IQVIA Biotech

Terminated

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Ovarian Cancer | Nonsmall Cell Lung Cancer

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
argenx
Iqvia Pty Ltd

Active, not recruiting

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) (rho)

Primary Sjögren's Syndrome

Belgium, Poland, Hungary, Netherlands
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

COVID-19 | SARS-CoV-2

United States, Chile, Peru
AstraZeneca
Iqvia Pty Ltd

Completed

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (MUSIC)

RSV Infection

United States, Belgium, Spain, Japan, Poland, South Africa, United Kingdom, Ukraine
GlaxoSmithKline
Iqvia Pty Ltd

Active, not recruiting

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (SWIFT-1)

Asthma

United States, France, Germany, Poland, Spain, Italy, United Kingdom, China, Canada, Czechia, Russian Federation, Ireland
GlaxoSmithKline
Iqvia Pty Ltd

Active, not recruiting

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (SWIFT-2)

Asthma

United States, Japan, Poland, Spain, Italy, Australia, Taiwan, France, Hungary, Canada, Czechia
AstraZeneca
Iqvia Pty Ltd

Terminated

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, France, Korea, Republic of, Spain, Czechia, Bulgaria, Australia, Poland
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

Neoplasms

United States, Spain, Netherlands, Canada
AstraZeneca
Iqvia Pty Ltd

Terminated

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

Hairy Cell Leukemia

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate

Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal Images

Kenya
AstraZeneca
Iqvia Pty Ltd

Withdrawn

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. (HESTIA5)

Sickle Cell Disease
Prokidney
PPD; Iqvia Pty Ltd

Active, not recruiting

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Chronic Kidney Diseases | Type 2 Diabetes Mellitus

United States, United Kingdom, Taiwan, Australia, Canada
Triomed AB
Iqvia Pty Ltd

Enrolling by invitation

Carry Life@ UF System Clinical Study

End Stage Renal Disease

Sweden, United Kingdom
Apple Inc.
Iqvia Pty Ltd

Completed

Atrial Fibrillation Algorithms Clinical Validation Study

Atrial Fibrillation

United States

Clinical Trials Sponsored by IQVIA RDS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations